CoChat
Sign Up
Cited by 58

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Structural Basis for Phosphoinositide Substrate Recognition, Catalysis, and Membrane Interactions in Human Inositol Polyphosphate 5-Phosphatases

Trésaugues, Lionel, Silvander, Camilla, Flodin, Susanne, Welin, Martin, Nyman, Tomas, Gräslund, Susanne, Hammarström, Martin, Berglund, Helena, Nordlund, Pär·2014·Structure
DOI 10.1016/j.str.2014.01.013
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.str.2014.01.013

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 68

  1. Amoasii, 2012, Myotubularin phosphoinositide phosphatases in human diseases. Curr. Top, Microbiol. Immunol., 362, 209
  2. Annis, 2009, Inhibitors of the lipid phosphatase SHIP2 discovered by high-throughput affinity selection-mass spectrometry screening of combinatorial libraries, Comb. Chem. High Throughput Screen., 12, 760, 10.2174/138620709789104870 · DOI
  3. Astle, 2006, Regulation of phosphoinositide signaling by the inositol polyphosphate 5-phosphatases, IUBMB Life, 58, 451, 10.1080/15216540600871159 · DOI
  4. Astle, 2007, The inositol polyphosphate 5-phosphatases: traffic controllers, waistline watchers and tumour suppressors?, Biochem. Soc. Symp., 161, 10.1042/BSS2007c15 · DOI
  5. Attree, 1992, The Lowe’s oculocerebrorenal syndrome gene encodes a protein highly homologous to inositol polyphosphate-5-phosphatase, Nature, 358, 239, 10.1038/358239a0 · DOI
  6. Azzedine, 2003, Mutations in MTMR13, a new pseudophosphatase homologue of MTMR2 and Sbf1, in two families with an autosomal recessive demyelinating form of Charcot-Marie-Tooth disease associated with early-onset glaucoma, Am. J. Hum. Genet., 72, 1141, 10.1086/375034 · DOI
  7. Beernink, 2001, Two divalent metal ions in the active site of a new crystal form of human apurinic/apyrimidinic endonuclease, Ape1: implications for the catalytic mechanism, J. Mol. Biol., 307, 1023, 10.1006/jmbi.2001.4529 · DOI
  8. Bielas, 2009, Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies, Nat. Genet., 41, 1032, 10.1038/ng.423 · DOI
  9. Blunt, 2012, Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia, Curr. Opin. Pharmacol., 12, 444, 10.1016/j.coph.2012.02.015 · DOI
  10. Bolino, 2000, Charcot-Marie-Tooth type 4B is caused by mutations in the gene encoding myotubularin-related protein-2, Nat. Genet., 25, 17, 10.1038/75542 · DOI
  11. Chen, 2010, MolProbity: all-atom structure validation for macromolecular crystallography, Acta Crystallogr. D Biol. Crystallogr., 66, 12, 10.1107/S0907444909042073 · DOI · Paper page
  12. Chi, 2004, Comparative mechanistic and substrate specificity study of inositol polyphosphate 5-phosphatase Schizosaccharomyces pombe Synaptojanin and SHIP2, J. Biol. Chem., 279, 44987, 10.1074/jbc.M406416200 · DOI
  13. Communi, 1996, Arginine 343 and 350 are two active residues involved in substrate binding by human Type I D-myo-inositol 1,4,5,-trisphosphate 5-phosphatase, J. Biol. Chem., 271, 11676, 10.1074/jbc.271.20.11676 · DOI
  14. Conduit, 2012, Inositol polyphosphate 5-phosphatases; new players in the regulation of cilia and ciliopathies, FEBS Lett., 586, 2846, 10.1016/j.febslet.2012.07.037 · DOI
  15. Dyson, 2005, The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2, Int. J. Biochem. Cell Biol., 37, 2260, 10.1016/j.biocel.2005.05.003 · DOI
  16. Eberhard, 1990, Evidence that the inositol phospholipids are necessary for exocytosis. Loss of inositol phospholipids and inhibition of secretion in permeabilized cells caused by a bacterial phospholipase C and removal of ATP, Biochem. J., 268, 15, 10.1042/bj2680015 · DOI
  17. Erdmann, 2007, A role of the Lowe syndrome protein OCRL in early steps of the endocytic pathway, Dev. Cell, 13, 377, 10.1016/j.devcel.2007.08.004 · DOI
  18. Fuhler, 2012, Therapeutic potential of SH2 domain-containing inositol-5′-phosphatase 1 (SHIP1) and SHIP2 inhibition in cancer, Mol. Med., 18, 65, 10.2119/molmed.2011.00178 · DOI · Paper page
  19. Gamper, 2007, Regulation of ion transport proteins by membrane phosphoinositides, Nat. Rev. Neurosci., 8, 921, 10.1038/nrn2257 · DOI
  20. Gorman, 1997, The crystal structure of the human DNA repair endonuclease HAP1 suggests the recognition of extra-helical deoxyribose at DNA abasic sites, EMBO J., 16, 6548, 10.1093/emboj/16.21.6548 · DOI
  21. Gräslund, 2008, The use of systematic N- and C-terminal deletions to promote production and structural studies of recombinant proteins, Protein Expr. Purif., 58, 210, 10.1016/j.pep.2007.11.008 · DOI
  22. Hakim, 2012, Inositol polyphosphate phosphatases in human disease, Curr. Top. Microbiol. Immunol., 362, 247
  23. Hartwig, 1995, Thrombin receptor ligation and activated Rac uncap actin filament barbed ends through phosphoinositide synthesis in permeabilized human platelets, Cell, 82, 643, 10.1016/0092-8674(95)90036-5 · DOI
  24. Hellsten, 2001, Disrupted sperm function and fertilin beta processing in mice deficient in the inositol polyphosphate 5-phosphatase Inpp5b, Dev. Biol., 240, 641, 10.1006/dbio.2001.0476 · DOI
  25. Hoopes, 2005, Dent Disease with mutations in OCRL1, Am. J. Hum. Genet., 76, 260, 10.1086/427887 · DOI
  26. Ichihara, 2013, Rational design and synthesis of 4-substituted 2-pyridin-2-ylamides with inhibitory effects on SH2 domain-containing inositol 5′-phosphatase 2 (SHIP2), Eur. J. Med. Chem., 62, 649, 10.1016/j.ejmech.2013.01.014 · DOI
  27. Jänne, 1998, Functional overlap between murine Inpp5b and Ocrl1 may explain why deficiency of the murine ortholog for OCRL1 does not cause Lowe syndrome in mice, J. Clin. Invest., 101, 2042, 10.1172/JCI2414 · DOI
  28. Jefferson, 1996, Mutation of the conserved domains of two inositol polyphosphate 5-phosphatases, Biochemistry, 35, 7890, 10.1021/bi9602627 · DOI
  29. Koch, 2005, The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading, Oncogene, 24, 3436, 10.1038/sj.onc.1208558 · DOI
  30. Ligresti, 2009, PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches, Cell Cycle, 8, 1352, 10.4161/cc.8.9.8255 · DOI · Paper page
  31. Lipton, 2008, Characterization of Mg2+ binding to the DNA repair protein apurinic/apyrimidic endonuclease 1 via solid-state 25Mg NMR spectroscopy, J. Am. Chem. Soc., 130, 9332, 10.1021/ja0776881 · DOI
  32. Liu, 2009, Targeting the phosphoinositide 3-kinase pathway in cancer, Nat. Rev. Drug Discov., 8, 627, 10.1038/nrd2926 · DOI
  33. Lomize, 2006, Positioning of proteins in membranes: a computational approach, Protein Sci., 15, 1318, 10.1110/ps.062126106 · DOI
  34. Lomize, 2012, OPM database and PPM web server: resources for positioning of proteins in membranes, Nucleic Acids Res., 40, D370, 10.1093/nar/gkr703 · DOI
  35. Maffucci, 2012, An introduction to phosphoinositides, Curr. Top. Microbiol. Immunol., 362, 1
  36. Mao, 2009, A PH domain within OCRL bridges clathrin-mediated membrane trafficking to phosphoinositide metabolism, EMBO J., 28, 1831, 10.1038/emboj.2009.155 · DOI
  37. Martin, 2001, PI(4,5)P(2) regulation of surface membrane traffic, Curr. Opin. Cell Biol., 13, 493, 10.1016/S0955-0674(00)00241-6 · DOI
  38. McCrea, 2009, Mutations in phosphoinositide metabolizing enzymes and human disease, Physiology (Bethesda), 24, 8, 10.1152/physiol.00035.2008 · DOI
  39. Michell, 2008, Inositol derivatives: evolution and functions, Nat. Rev. Mol. Cell Biol., 9, 151, 10.1038/nrm2334 · DOI
  40. Mills, 2012, A synthetic polyphosphoinositide headgroup surrogate in complex with SHIP2 provides a rationale for drug discovery, ACS Chem. Biol., 7, 822, 10.1021/cb200494d · DOI
  41. Mol, 2000, DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination [corrected], Nature, 403, 451, 10.1038/35000249 · DOI
  42. Moses, 2009, In vitro and in vivo activity of novel small-molecule inhibitors targeting the pleckstrin homology domain of protein kinase B/AKT, Cancer Res., 69, 5073, 10.1158/0008-5472.CAN-08-3839 · DOI
  43. Oezguen, 2007, A “moving metal mechanism” for substrate cleavage by the DNA repair endonuclease APE-1, Proteins, 68, 313, 10.1002/prot.21397 · DOI
  44. Oezguen, 2011, MD simulation and experimental evidence for Mg²+ binding at the B site in human AP endonuclease 1, Bioinformation, 7, 184, 10.6026/97320630007184 · DOI
  45. Ooms, 2009, The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease, Biochem. J., 419, 29, 10.1042/BJ20081673 · DOI
  46. Pesesse, 1998, The SH2 domain containing inositol 5-phosphatase SHIP2 displays phosphatidylinositol 3,4,5-trisphosphate and inositol 1,3,4,5-tetrakisphosphate 5-phosphatase activity, FEBS Lett., 437, 301, 10.1016/S0014-5793(98)01255-1 · DOI
  47. Pirruccello, 2012, Inositol 5-phosphatases: insights from the Lowe syndrome protein OCRL, Trends Biochem. Sci., 37, 134, 10.1016/j.tibs.2012.01.002 · DOI
  48. Poccia, 2009, Phosphatidylinositol metabolism and membrane fusion, Biochem. J., 418, 233, 10.1042/BJ20082105 · DOI
  49. Prasad, 2001, SH2-containing inositol 5′-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading, Mol. Cell. Biol., 21, 1416, 10.1128/MCB.21.4.1416-1428.2001 · DOI
  50. Samuels, 2004, High frequency of mutations of the PIK3CA gene in human cancers, Science, 304, 554, 10.1126/science.1096502 · DOI
  51. Sasaoka, 2006, Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity, Pharmacol. Ther., 112, 799, 10.1016/j.pharmthera.2006.06.001 · DOI
  52. Schmid, 2004, Type II phosphoinositide 5-phosphatases have unique sensitivities towards fatty acid composition and head group phosphorylation, FEBS Lett., 576, 9, 10.1016/j.febslet.2004.08.052 · DOI
  53. Senderek, 2003, Mutation of the SBF2 gene, encoding a novel member of the myotubularin family, in Charcot-Marie-Tooth neuropathy type 4B2/11p15, Hum. Mol. Genet., 12, 349, 10.1093/hmg/ddg030 · DOI
  54. Sleeman, 2005, Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity, Nat. Med., 11, 199, 10.1038/nm1178 · DOI
  55. Stenton, 2013, Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 2. Efficacy studies in allergic and pulmonary inflammation models in vivo, Br. J. Pharmacol., 168, 1519, 10.1111/bph.12038 · DOI
  56. Stenton, 2013, Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo, Br. J. Pharmacol., 168, 1506, 10.1111/bph.12039 · DOI
  57. Suwa, 2009, Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2, Br. J. Pharmacol., 158, 879, 10.1111/j.1476-5381.2009.00358.x · DOI
  58. Suwa, 2010, Glucose metabolism activation by SHIP2 inhibitors via up-regulation of GLUT1 gene in L6 myotubes, Eur. J. Pharmacol., 642, 177, 10.1016/j.ejphar.2010.06.002 · DOI
  59. Tolias, 2000, Type Ialpha phosphatidylinositol-4-phosphate 5-kinase mediates Rac-dependent actin assembly, Curr. Biol., 10, 153, 10.1016/S0960-9822(00)00315-8 · DOI
  60. Tsujishita, 2001, Specificity determinants in phosphoinositide dephosphorylation: crystal structure of an archetypal inositol polyphosphate 5-phosphatase, Cell, 105, 379, 10.1016/S0092-8674(01)00326-9 · DOI
  61. Tsutakawa, 2013, Conserved structural chemistry for incision activity in structurally non-homologous apurinic/apyrimidinic endonuclease APE1 and endonuclease IV DNA repair enzymes, J. Biol. Chem., 288, 8445, 10.1074/jbc.M112.422774 · DOI
  62. Ungewickell, 2004, The inositol polyphosphate 5-phosphatase Ocrl associates with endosomes that are partially coated with clathrin, Proc. Natl. Acad. Sci. USA, 101, 13501, 10.1073/pnas.0405664101 · DOI
  63. Vanhaesebroeck, 1997, Phosphoinositide 3-kinases: a conserved family of signal transducers, Trends Biochem. Sci., 22, 267, 10.1016/S0968-0004(97)01061-X · DOI
  64. Waugh, 2012, Phosphatidylinositol 4-kinases, phosphatidylinositol 4-phosphate and cancer, Cancer Lett., 325, 125, 10.1016/j.canlet.2012.06.009 · DOI
  65. Whisstock, 2000, The inositol polyphosphate 5-phosphatases and the apurinic/apyrimidinic base excision repair endonucleases share a common mechanism for catalysis, J. Biol. Chem., 275, 37055, 10.1074/jbc.M006244200 · DOI
  66. Wisniewski, 1999, A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells, Blood, 93, 2707, 10.1182/blood.V93.8.2707 · DOI · Paper page
  67. Yin, 2008, PTEN: a new guardian of the genome, Oncogene, 27, 5443, 10.1038/onc.2008.241 · DOI
  68. Zhang, 2013, Novel OCRL mutations in Chinese children with Lowe syndrome, World J. Pediatr., 9, 53, 10.1007/s12519-013-0406-4 · DOI

Cited by

Sorted by citations

See all 58

Metadata

Authors
Trésaugues, L., Silvander, C., Flodin, S., Welin, M., Nyman, T., Gräslund, S., Hammarström, M., Berglund, H., & Nordlund, P.
Venue
Structure
Publisher
Elsevier BV
Published
2014-05
Volume
22
Issue
5
Pages
744-755
ISSN
0969-2126
DOI
10.1016/j.str.2014.01.013
Cited by
58
References
3
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review